Abstract
Summary
A retropharyngeal abscess is a serious infection, usually starts in the lymph nodes, characterised by collection of pus at the back of the throat. Retropharyngeal abscess typically occurs in children under the age of eight, sometimes it can also affect adults. The symptoms of retropharyngeal abscess include difficulty or noisy breathing, difficulty and pain while swallowing, drooling, severe cough, severe throat pain, neck stiffness or swelling, muscle spasms in the neck among others. Retropharyngeal abscess is generally preceded by upper respiratory infections mostly a middle ear or sinus infection.
LPI (LP Information)' newest research report, the “Retropharyngeal Abscess Industry Forecast” looks at past sales and reviews total world Retropharyngeal Abscess sales in 2022, providing a comprehensive analysis by region and market sector of projected Retropharyngeal Abscess sales for 2023 through 2029. With Retropharyngeal Abscess sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Retropharyngeal Abscess industry.
This Insight Report provides a comprehensive analysis of the global Retropharyngeal Abscess landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Retropharyngeal Abscess portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Retropharyngeal Abscess market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Retropharyngeal Abscess and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Retropharyngeal Abscess.
The global Retropharyngeal Abscess market size is projected to grow from US$ 4381 million in 2022 to US$ 5260.1 million in 2029; it is expected to grow at a CAGR of 2.6% from 2023 to 2029.
A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.
This report presents a comprehensive overview, market shares, and growth opportunities of Retropharyngeal Abscess market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Antibiotics
Pain Killers
Surgical Drainage
Others
Segmentation by application
Hospitals and Clinics
Research and Academics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck KGaA
Johnson & Johnson
AstraZeneca plc.
Sanofi S.A.
Pfizer
Mylan N.V.
Novartis AG
Teva pharmaceutical company
GlaxoSmithKline plc.
LPI (LP Information)' newest research report, the “Retropharyngeal Abscess Industry Forecast” looks at past sales and reviews total world Retropharyngeal Abscess sales in 2022, providing a comprehensive analysis by region and market sector of projected Retropharyngeal Abscess sales for 2023 through 2029. With Retropharyngeal Abscess sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Retropharyngeal Abscess industry.
This Insight Report provides a comprehensive analysis of the global Retropharyngeal Abscess landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Retropharyngeal Abscess portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Retropharyngeal Abscess market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Retropharyngeal Abscess and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Retropharyngeal Abscess.
The global Retropharyngeal Abscess market size is projected to grow from US$ 4381 million in 2022 to US$ 5260.1 million in 2029; it is expected to grow at a CAGR of 2.6% from 2023 to 2029.
A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.
This report presents a comprehensive overview, market shares, and growth opportunities of Retropharyngeal Abscess market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Antibiotics
Pain Killers
Surgical Drainage
Others
Segmentation by application
Hospitals and Clinics
Research and Academics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck KGaA
Johnson & Johnson
AstraZeneca plc.
Sanofi S.A.
Pfizer
Mylan N.V.
Novartis AG
Teva pharmaceutical company
GlaxoSmithKline plc.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Retropharyngeal Abscess Market Size 2018-2029
2.1.2 Retropharyngeal Abscess Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Retropharyngeal Abscess Segment by Type
2.2.1 Antibiotics
2.2.2 Pain Killers
2.2.3 Surgical Drainage
2.2.4 Others
2.3 Retropharyngeal Abscess Market Size by Type
2.3.1 Retropharyngeal Abscess Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Retropharyngeal Abscess Market Size Market Share by Type (2018-2023)
2.4 Retropharyngeal Abscess Segment by Application
2.4.1 Hospitals and Clinics
2.4.2 Research and Academics
2.4.3 Others
2.5 Retropharyngeal Abscess Market Size by Application
2.5.1 Retropharyngeal Abscess Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Retropharyngeal Abscess Market Size Market Share by Application (2018-2023)
3 Retropharyngeal Abscess Market Size by Player
3.1 Retropharyngeal Abscess Market Size Market Share by Players
3.1.1 Global Retropharyngeal Abscess Revenue by Players (2018-2023)
3.1.2 Global Retropharyngeal Abscess Revenue Market Share by Players (2018-2023)
3.2 Global Retropharyngeal Abscess Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Retropharyngeal Abscess by Regions
4.1 Retropharyngeal Abscess Market Size by Regions (2018-2023)
4.2 Americas Retropharyngeal Abscess Market Size Growth (2018-2023)
4.3 APAC Retropharyngeal Abscess Market Size Growth (2018-2023)
4.4 Europe Retropharyngeal Abscess Market Size Growth (2018-2023)
4.5 Middle East & Africa Retropharyngeal Abscess Market Size Growth (2018-2023)
5 Americas
5.1 Americas Retropharyngeal Abscess Market Size by Country (2018-2023)
5.2 Americas Retropharyngeal Abscess Market Size by Type (2018-2023)
5.3 Americas Retropharyngeal Abscess Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Retropharyngeal Abscess Market Size by Region (2018-2023)
6.2 APAC Retropharyngeal Abscess Market Size by Type (2018-2023)
6.3 APAC Retropharyngeal Abscess Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Retropharyngeal Abscess by Country (2018-2023)
7.2 Europe Retropharyngeal Abscess Market Size by Type (2018-2023)
7.3 Europe Retropharyngeal Abscess Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Retropharyngeal Abscess by Region (2018-2023)
8.2 Middle East & Africa Retropharyngeal Abscess Market Size by Type (2018-2023)
8.3 Middle East & Africa Retropharyngeal Abscess Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Retropharyngeal Abscess Market Forecast
10.1 Global Retropharyngeal Abscess Forecast by Regions (2024-2029)
10.1.1 Global Retropharyngeal Abscess Forecast by Regions (2024-2029)
10.1.2 Americas Retropharyngeal Abscess Forecast
10.1.3 APAC Retropharyngeal Abscess Forecast
10.1.4 Europe Retropharyngeal Abscess Forecast
10.1.5 Middle East & Africa Retropharyngeal Abscess Forecast
10.2 Americas Retropharyngeal Abscess Forecast by Country (2024-2029)
10.2.1 United States Retropharyngeal Abscess Market Forecast
10.2.2 Canada Retropharyngeal Abscess Market Forecast
10.2.3 Mexico Retropharyngeal Abscess Market Forecast
10.2.4 Brazil Retropharyngeal Abscess Market Forecast
10.3 APAC Retropharyngeal Abscess Forecast by Region (2024-2029)
10.3.1 China Retropharyngeal Abscess Market Forecast
10.3.2 Japan Retropharyngeal Abscess Market Forecast
10.3.3 Korea Retropharyngeal Abscess Market Forecast
10.3.4 Southeast Asia Retropharyngeal Abscess Market Forecast
10.3.5 India Retropharyngeal Abscess Market Forecast
10.3.6 Australia Retropharyngeal Abscess Market Forecast
10.4 Europe Retropharyngeal Abscess Forecast by Country (2024-2029)
10.4.1 Germany Retropharyngeal Abscess Market Forecast
10.4.2 France Retropharyngeal Abscess Market Forecast
10.4.3 UK Retropharyngeal Abscess Market Forecast
10.4.4 Italy Retropharyngeal Abscess Market Forecast
10.4.5 Russia Retropharyngeal Abscess Market Forecast
10.5 Middle East & Africa Retropharyngeal Abscess Forecast by Region (2024-2029)
10.5.1 Egypt Retropharyngeal Abscess Market Forecast
10.5.2 South Africa Retropharyngeal Abscess Market Forecast
10.5.3 Israel Retropharyngeal Abscess Market Forecast
10.5.4 Turkey Retropharyngeal Abscess Market Forecast
10.5.5 GCC Countries Retropharyngeal Abscess Market Forecast
10.6 Global Retropharyngeal Abscess Forecast by Type (2024-2029)
10.7 Global Retropharyngeal Abscess Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Merck KGaA
11.1.1 Merck KGaA Company Information
11.1.2 Merck KGaA Retropharyngeal Abscess Product Offered
11.1.3 Merck KGaA Retropharyngeal Abscess Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Merck KGaA Main Business Overview
11.1.5 Merck KGaA Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Retropharyngeal Abscess Product Offered
11.2.3 Johnson & Johnson Retropharyngeal Abscess Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 AstraZeneca plc.
11.3.1 AstraZeneca plc. Company Information
11.3.2 AstraZeneca plc. Retropharyngeal Abscess Product Offered
11.3.3 AstraZeneca plc. Retropharyngeal Abscess Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 AstraZeneca plc. Main Business Overview
11.3.5 AstraZeneca plc. Latest Developments
11.4 Sanofi S.A.
11.4.1 Sanofi S.A. Company Information
11.4.2 Sanofi S.A. Retropharyngeal Abscess Product Offered
11.4.3 Sanofi S.A. Retropharyngeal Abscess Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Sanofi S.A. Main Business Overview
11.4.5 Sanofi S.A. Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Retropharyngeal Abscess Product Offered
11.5.3 Pfizer Retropharyngeal Abscess Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 Mylan N.V.
11.6.1 Mylan N.V. Company Information
11.6.2 Mylan N.V. Retropharyngeal Abscess Product Offered
11.6.3 Mylan N.V. Retropharyngeal Abscess Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Mylan N.V. Main Business Overview
11.6.5 Mylan N.V. Latest Developments
11.7 Novartis AG
11.7.1 Novartis AG Company Information
11.7.2 Novartis AG Retropharyngeal Abscess Product Offered
11.7.3 Novartis AG Retropharyngeal Abscess Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Novartis AG Main Business Overview
11.7.5 Novartis AG Latest Developments
11.8 Teva pharmaceutical company
11.8.1 Teva pharmaceutical company Company Information
11.8.2 Teva pharmaceutical company Retropharyngeal Abscess Product Offered
11.8.3 Teva pharmaceutical company Retropharyngeal Abscess Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Teva pharmaceutical company Main Business Overview
11.8.5 Teva pharmaceutical company Latest Developments
11.9 GlaxoSmithKline plc.
11.9.1 GlaxoSmithKline plc. Company Information
11.9.2 GlaxoSmithKline plc. Retropharyngeal Abscess Product Offered
11.9.3 GlaxoSmithKline plc. Retropharyngeal Abscess Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 GlaxoSmithKline plc. Main Business Overview
11.9.5 GlaxoSmithKline plc. Latest Developments
12 Research Findings and Conclusion